Targeting P2Y limits T17 accumulation in the CNS and reduces EAE progression.

Huntemann N, Preuth L-M, Krug TF, Vogelsang A, Groeneweg L, Disse P, Therpurakal R N, Zarbock A, Nieswandt B, Göbel K, et al.